On LinkedIn, the Pune, India-based company labeled InsuPatch “India’s first tubeless, affordable, patch-style insulin infusion pump.”

“Diabetes touches millions of lives across India — shaping routines, emotions, families, and futures,” the company wrote. “For individuals who depend on insulin every single day, the journey is even more demanding. At Renu MedTech, we are proud to introduce InsuPatch, a made-in-India, tubeless, patch-style insulin infusion pump — designed specifically for Indian users, Indian conditions, and Indian healthcare realities.”

Insulet is the current leader in the insulin patch pump space with its tubeless, automated Omnipod 5. According to Insulet’s website, Omnipod is not available in India, potentially presenting an opportunity for Renu MedTech. Its patch pump could join a market that features many planned entries, including from Medtronic, Tandem Diabetes Care and Beta Bionics. Some of those could even be on the horizon within the next year. ViCentra, PharmaSens, U-Pump and Modular Medical are among the other names in the patch pump space as well.